These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 14529064)

  • 1. Levetiracetam: a new therapeutic option for refractory epilepsy.
    Pinto A; Sander JW
    Int J Clin Pract; 2003 Sep; 57(7):616-21. PubMed ID: 14529064
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of levetiracetam: a review of three pivotal clinical trials.
    Privitera M
    Epilepsia; 2001; 42 Suppl 4():31-5. PubMed ID: 11564123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The SKATE study: an open-label community-based study of levetiracetam as add-on therapy for adults with uncontrolled partial epilepsy.
    Steinhoff BJ; Somerville ER; Van Paesschen W; Ryvlin P; Schelstraete I
    Epilepsy Res; 2007 Aug; 76(1):6-14. PubMed ID: 17681453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Once-daily extended-release levetiracetam as adjunctive treatment of partial-onset seizures in patients with epilepsy: a double-blind, randomized, placebo-controlled trial.
    Peltola J; Coetzee C; Jiménez F; Litovchenko T; Ramaratnam S; Zaslavaskiy L; Lu ZS; Sykes DM;
    Epilepsia; 2009 Mar; 50(3):406-14. PubMed ID: 19317886
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Levetiracetam for people with mental retardation and refractory epilepsy.
    Kelly K; Stephen LJ; Brodie MJ
    Epilepsy Behav; 2004 Dec; 5(6):878-83. PubMed ID: 15582836
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in Chinese patients with refractory partial-onset seizures.
    Wu XY; Hong Z; Wu X; Wu LW; Wang XF; Zhou D; Zhao ZX; Lv CZ
    Epilepsia; 2009 Mar; 50(3):398-405. PubMed ID: 18657175
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Levetiracetam in clinical practice: long-term experience in patients with refractory epilepsy referred to a tertiary epilepsy center.
    Bootsma HP; Ricker L; Diepman L; Gehring J; Hulsman J; Lambrechts D; Leenen L; Majoie M; Schellekens A; de Krom M; Aldenkamp AP
    Epilepsy Behav; 2007 Mar; 10(2):296-303. PubMed ID: 17317325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term use of Levetiracetam in patients with severe childhood-onset epilepsy.
    von Stuelpnagel C; Holthausen H; Kluger G
    Eur J Paediatr Neurol; 2007 Nov; 11(6):341-5. PubMed ID: 17442601
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preliminary efficacy of levetiracetam in monotherapy.
    Ben-Menachem E
    Epileptic Disord; 2003 May; 5 Suppl 1():S51-5. PubMed ID: 12915342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An open-label study of levetiracetam at individualised doses between 1000 and 3000 mg day(-1) in adult patients with refractory epilepsy.
    Abou-Khalil B; Hemdal P; Privitera MD
    Seizure; 2003 Apr; 12(3):141-9. PubMed ID: 12651078
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monotherapy for partial epilepsy: focus on levetiracetam.
    Gambardella A; Labate A; Colosimo E; Ambrosio R; Quattrone A
    Neuropsychiatr Dis Treat; 2008 Feb; 4(1):33-8. PubMed ID: 18728811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Measurement of seizure freedom in adjunctive therapy studies in refractory partial epilepsy: the levetiracetam experience.
    Leppik I; De Rue K; Edrich P; Perucca E
    Epileptic Disord; 2006 Jun; 8(2):118-30. PubMed ID: 16793573
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of levetiracetam in hospitalized patients.
    Falip M; Carreño M; Amaro S; Donaire A; Delgado R; Toledo M; Maestro I
    Epilepsia; 2006 Dec; 47(12):2186-8. PubMed ID: 17201722
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjunctive levetiracetam in infants and young children with refractory partial-onset seizures.
    Piña-Garza JE; Nordli DR; Rating D; Yang H; Schiemann-Delgado J; Duncan B;
    Epilepsia; 2009 May; 50(5):1141-9. PubMed ID: 19243423
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized-controlled trials of levetiracetam as an adjunctive therapy in epilepsy of multiple seizure types.
    Fang Y; Wu X; Xu L; Tang X; Wang J; Zhu G; Hong Z
    J Clin Neurosci; 2014 Jan; 21(1):55-62. PubMed ID: 24231559
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of levetiracetam (3,000 mg/Day) as an adjunctive therapy in Chinese patients with refractory partial seizures.
    Xiao Z; Li JM; Wang XF; Xiao F; Xi ZQ; Lv Y; Sun HB
    Eur Neurol; 2009; 61(4):233-9. PubMed ID: 19176965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Benefit of combination therapy in epilepsy: a review of the preclinical evidence with levetiracetam.
    Kaminski RM; Matagne A; Patsalos PN; Klitgaard H
    Epilepsia; 2009 Mar; 50(3):387-97. PubMed ID: 18627416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Onset of action of levetiracetam: a RCT trial using therapeutic intensive seizure analysis (TISA).
    Stefan H; Wang-Tilz Y; Pauli E; Dennhöfer S; Genow A; Kerling F; Lorber B; Fraunberger B; Halboni P; Koebnick C; Gefeller O; Tilz C
    Epilepsia; 2006 Mar; 47(3):516-22. PubMed ID: 16529615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety profile of levetiracetam.
    Arroyo S; Crawford P
    Epileptic Disord; 2003 May; 5 Suppl 1():S57-63. PubMed ID: 12915343
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical predictors in patients with refractory epilepsy exposed to levetiracetam: a single-center study.
    Peltola J; Peltola M; Auvinen A; Keränen T; Liimatainen S; Kharazmi E; Fallah M
    Acta Neurol Scand; 2008 May; 117(5):332-6. PubMed ID: 18081915
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.